The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
Abstract
OBJECTIVE: To determine calcitonin gene-related peptide (CGRP) levels outside migraine attacks in peripheral blood as a potential biomarker for chronic migraine (CM). METHODS: Women older than 17 years and diagnosed with CM were recruited. Matched healthy women with no headache history and women with episodic migraine (EM) served as control groups, together with a series of patients with episodic cluster headache in a pain-free period. CGRP levels were determined in blood samples obtained from the right antecubital vein by ELISA outside a migraine attack and having taken no symptomatic medication the day before. For ethical reasons, preventatives were not stopped. RESULTS: We assessed plasma samples from 103 women with CM, 31 matched healthy women, 43 matched women with EM, and 14 patients with episodic cluster headache matched for age. CGRP levels were significantly increased in CM (74.90 pg/mL) as compared with control healthy women (33.74 pg/mL), women with EM (46.37 pg/mL), and patients with episodic cluster headache (45.87 pg/mL). Thresholds of 43.45 and 58.22 pg/mL optimize the sensitivity and specificity to differentiate CM from healthy controls and EM, respectively. In the CM group, CGRP levels were significantly increased in women with a history of migraine with aura vs those only experiencing migraine without aura. Variables such as age, analgesic overuse, depression, fibromyalgia, vascular risk factors, history of triptan consumption, or kind of preventative treatment did not significantly influence CGRP levels. CONCLUSION: Increased CGRP level measured in peripheral blood outside migraine attacks and in the absence of symptomatic medication could be a biomarker helping in the diagnosis of CM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Central sensitization, along with dysfunctional descending pain modulation, could promote the progression and persistence of symptoms, as well as the development of a chronic form of the disease [73].”
From Effectiveness of acceptance and commitment therapy in central pain sensitization syndromes: A systematic review (2021) · cites this paper as [73]
Citations
Cites
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L. I., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,603
Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model
Bolay, H., Reuter, U., Dunn, A. K., Huang, Z., Boas, D. A., & Moskowitz, M. A. (2002) · Nature Medicine · doi:10.1038/nm0202-136 · Cited by 1,214
Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
Olesen, J., Diener, H., Husstedt, I. W., Goadsby, P. J., Hall, D. B., Meier, U., Pollentier, S., & Lesko, L. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030505 · Cited by 1,190
Goadsby, P. J., & Edvinsson, L. I. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,164
Cgrp May Play A Causative Role in Migraine
Lassen, L., Haderslev, P. A., Jacobsen, V. B., Iversen, H. K., Sperling, B. K., & Olesen, J. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00310.x · Cited by 1,029
New Appendix Criteria Open for a Broader Concept of Chronic Migraine
Olesen, J., Bousser, M.-G., Diener, H.-C., Dodick, D., First, M., Goadsby, P., Göbel, H., Lainez, M., Lance, J., Lipton, R., et al. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01172.x · Cited by 909 · cited 2×
“The International Headache Society (IHS) defines CM as 15 or more headache days per month for at least 3 months, with 8 or more days per month fulfilling migraine criteria, in the absence of medication overuse.(1) Migraine is considered to be a neurovascular disorder.”
BackgroundMethodSensitization of meningeal sensory neurons and the origin of headaches
Strassman, A. M., Raymond, S. A., & Burstein, R. (1996) · Nature · doi:10.1038/384560a0 · Cited by 704
Goadsby, P. J., & Edvinsson, L. I. (1994) · Brain · doi:10.1093/brain/117.3.427 · Cited by 683
Origin of pain in migraine: evidence for peripheral sensitisation
Olesen, J., Burstein, R., Ashina, M., & Tfelt‐Hansen, P. C. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70090-0 · Cited by 563
CGRP and its receptors provide new insights into migraine pathophysiology
Ho, T. W., Edvinsson, L. I., & Goadsby, P. J. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.127 · Cited by 533
Cited by
Sorted by citations
Galvez-Sánchez, C. M., Montoro, C. I., Moreno-Padilla, M., Reyes del Paso, G. A., & de la Coba, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122706 · Cited by 45
“Central sensitization, along with dysfunctional descending pain modulation, could promote the progression and persistence of symptoms, as well as the development of a chronic form of the disease [73].”
BackgroundLiu, Y., Chen, Q.-Y., Lee, J. H., Li, X.-H., Yu, S., & Zhuo, M. (2020) · Molecular Brain · doi:10.1186/s13041-020-00580-x · Cited by 26
Metadata
- Authors
- Cernuda-Morollón, E., Larrosa, D., Ramón, C., Vega, J., Martínez-Camblor, P., & Pascual, J.
- Affiliations
- From Neuroscience Area, Service of Neurology and Faculty of Medicine, University Hospital Central de Asturias and INEUROPA (E.C.-M, D.L., C.R., J.V., J.P.), and Oficina de Investigación Biosanitaria OIB (P.M.-C), Oviedo, Asturias, Spain.
- Hospital Universitario Central de Asturias (ES)
- Venue
- Neurology
- Published
- 2013-10
- Volume
- 81
- Issue
- 14
- Pages
- 1191-1196
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2155971820
- Cited by
- 468
- References
- 32
- Citations by year
- 2026: 25 · 2025: 44 · 2024: 66 · 2023: 39 · 2022: 52 · 2021: 42 · 2020: 37 · 2019: 43 · 2018: 24 · 2017: 34 · 2016: 16 · 2015: 23 · 2014: 19 · 2013: 4
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- calcitonin gene-related peptide, chronic migraine, episodic migraine, cluster headache, biomarkers, plasma CGRP levels, migraine with aura, migraine without aura, diagnostic thresholds, women
- MeSH terms
- Adolescent, Adult, Aged, Chronic Disease, Cluster Headache, Female, Humans, Male, Middle Aged, Migraine Disorders, Biomarkers, Calcitonin Gene-Related Peptide, Up-Regulation, Migraine with Aura, Migraine without Aura, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
